Skip to main content

Table 2 CIP2A immunostaining intensity in benign prostatic hyperplasia and prostate cancer.

From: CIP2A expression is increased in prostate cancer

  

CIP2A immunostaining

 

n

negative

positive

Hyperplasia

20

18 (90.0%)

2 (10.0%)

Prostate cancer

59

16 (27.1%)

43 (72.9%)

  1. p < 0.001 (Fisher's exact test)
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us